Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tejpar

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Acta Gastro-Enterologica Belgica|November 23, 2011
Familial adenomatous polyposis: clinical presentation, detection and surveillanceS Laurent, D Franchimont, J P Coppens, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'G Folprecht, M Morfouace, M Collienne, et al.
Virchows Archiv : an International Journal of Pathology|September 20, 2008
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programJ H J M van Krieken, A Jung, T Kirchner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker studyR Dienstmann, M J Mason, F A Sinicrope, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
Virchows Archiv : an International Journal of Pathology|December 18, 2012
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assuranceJ R Dijkstra, D A M Heideman, G A Meijer, et al.
ESMO Open|December 3, 2025
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trialE Elez, S Siena, A Sartore-Bianchi, et al.
Gut|April 15, 2000
Analysis of genetic and phenotypic heterogeneity in juvenile polyposisK Woodford-Richens, S Bevan, M Churchman, et al.
Gut|January 16, 2008
Guidelines for the clinical management of familial adenomatous polyposis (FAP)H F A Vasen, G Möslein, A Alonso, et al.
Gut|June 29, 2010
Peutz-Jeghers syndrome: a systematic review and recommendations for managementA D Beggs, A R Latchford, H F A Vasen, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Acta Gastro-Enterologica Belgica|November 23, 2011
Familial adenomatous polyposis: clinical presentation, detection and surveillanceS Laurent, D Franchimont, J P Coppens, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'G Folprecht, M Morfouace, M Collienne, et al.
Virchows Archiv : an International Journal of Pathology|September 20, 2008
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programJ H J M van Krieken, A Jung, T Kirchner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker studyR Dienstmann, M J Mason, F A Sinicrope, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
Virchows Archiv : an International Journal of Pathology|December 18, 2012
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assuranceJ R Dijkstra, D A M Heideman, G A Meijer, et al.
ESMO Open|December 3, 2025
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trialE Elez, S Siena, A Sartore-Bianchi, et al.
Gut|April 15, 2000
Analysis of genetic and phenotypic heterogeneity in juvenile polyposisK Woodford-Richens, S Bevan, M Churchman, et al.
Gut|January 16, 2008
Guidelines for the clinical management of familial adenomatous polyposis (FAP)H F A Vasen, G Möslein, A Alonso, et al.
Gut|June 29, 2010
Peutz-Jeghers syndrome: a systematic review and recommendations for managementA D Beggs, A R Latchford, H F A Vasen, et al.
Pageof 5